EUCTR2005-005717-38-GB进行中（未招募）1 期
An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Provision of informed consent Male or female aged 18 years or older Histological or cytological confirmation of GIST which is resistant or intolerant to imatinib mesylate, or metastatic STS, which is refractory to standard therapies or for which no standard therapy exists WHO Performance status 0 – 2 Life expectancy of > 12 weeks One or more measurable lesions at least 10mm in the longest diameter by spiral computed tomography (CT) scan or 20 mm with conventional techniques (and for GIST patients this must be at least 20mm by any technique as a modification of RECIST). Provision of informed consent for genetic research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Untreated unstable brain or meningeal metastases. Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either: - do not require corticosteroids or - have been treated with corticosteroids, with clinical and radiological evidence of brain metastases stabilisation at least 10 days after discontinuation of steroids. 2. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count less than or equal 1.5 x 10 power 9 /L or platelet count less than or equal 100 x 10 power 9 /L or requiring regular blood transfusions to maintain haemoglobin >9 g/dL. 3. Serum bilirubin greater than or equal 1.5 x upper limit of reference range (ULRR). 4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal 2.5 x ULRR. If liver metastases are present, ALT or AST >5 x ULRR. 5. Serum creatinine >1.5 x ULRR or a creatinine clearance of less than or equal 50mL/min calculated by Cockcroft-Gault. 6. Greater than +1 proteinuria on 2 consecutive dipsticks taken no less than 1 week apart unless urinary protein <1.5 g in a 24 hour urine collection. 7. Patients with a history of poorly controlled hypertension with resting BP >150/100 mmHg in the presence or absence of a stable regimen of anti hypertensive therapy. 8. Any evidence of severe or uncontrolled systemic diseases (eg, unstable or uncompensated respiratory, cardiac including arrhythmias, hepatic or renal disease), including known infection with Hepatitis B or C virus or human immunodeficiency virus. 9. Unresolved toxicity >CTC grade 2 from previous anti-cancer therapy except alopecia (if applicable). 10. Mean QTc with Bazett’s correction >470 msec in screening electrocardiogram (ECG) or history of familial long QT syndrome (as per International Conference on Harmonisation [ICH] guideline E14). 11.Significant haemorrhage (>30 ml bleeding/episode in previous 3 months) or haemoptysis (>5 ml fresh blood in previous 4 weeks). 12. Recent (<14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed. 13. Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication. 14. Known severe hypersensitivity to AZD2171 or any of its excipients. 15. Other concomitant anti cancer therapy, except steroids. 16. Known severe hypersensitivity to beta blockers or calcium channel blockers. 17. History of other malignancies within 5 years except for adequately treated basal or squamous cell cancer or carcinoma in situ. 18. History of CNS disorders or uncontrolled seizures. 19. History of significant gastrointestinal impairment (unrelated to GIST), as judged by the investigator that would significantly affect the absorption of AZD2171. 20. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at the study site). 21. Previous enrolment or randomisation of treatment in the present study. 22. Treatment with an investigational drug within 30 days prior to starting AZD2171, with the exception of SU11248 and imatinib mesylate which should be stopped at least 14 days before starting AZD2171.
研究者
相似试验
尚未招募
不适用
Phase II, Open Label Study in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma(HER-2 Amplified or Co-Expressing HER-1 and HER 2)NeoplasmsKCT0000348Pharmanet Korea24
已完成
2 期
Study drug ELX-02 for patients with Alport syndromeGenetic DiseasesOther specified congenital malformation syndromes, not elsewhere classifiedAlport syndromeISRCTN12014920Eloxx Pharmaceuticals (United States)3
进行中（未招募）
不适用
A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients with Solar Urticaria (SU) - Phase II SU Pilot StudySolar Urticaria (SU)MedDRA version: 9.1Level: LLTClassification code 10041307Term: Solar urticariaEUCTR2007-001068-55-GBClinuvel Pharmaceuticals Limited
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102
招募中
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-FRAVA Therapeutics B.V.102